A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03207009|
Recruitment Status : Completed
First Posted : July 2, 2017
Last Update Posted : April 4, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Beta-Thalassemia||Genetic: LentiGlobin BB305 Drug Product||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||18 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase 3 Single Arm Study Evaluating the Efficacy and Safety of Gene Therapy in Subjects With Transfusion-dependent β-Thalassemia by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With a Lentiviral βA-T87Q-Globin Vector in Subjects ≤50 Years of Age|
|Actual Study Start Date :||June 8, 2017|
|Actual Primary Completion Date :||November 15, 2022|
|Actual Study Completion Date :||November 15, 2022|
Experimental: LentiGlobin BB305 Drug Product
LentiGlobin BB305 Drug Product (autologous CD34+ cell-enriched population that contains cells transduced with LentiGlobin BB305 lentiviral vector encoding human βA-T87Q-globin)
Genetic: LentiGlobin BB305 Drug Product
LentiGlobin BB305 Drug Product is administered by IV infusion following myeloablative conditioning with busulfan.
Other Name: betibeglogene autotemcel
- Proportion of Participants who meet the Definition of Transfusion Independence (TI) [ Time Frame: From 12 to 24 months post-transplant ]TI is defined as greater than or equal to (>=) 9 grams per deciliter (g/dL) without any packed red blood cell (pRBC) transfusions for a continuous period of >=12 months at any time during the study after drug product infusion.
- Proportion of Participants who meet the Definition of Transfusion Independence (TI) at Month 24 [ Time Frame: At Month 24 post-transplant ]
- Duration of Transfusion Independence (TI) [ Time Frame: Up to 24 months post-transplant ]
- Time From Drug Product Infusion to Achievement of Transfusion Independence (TI) [ Time Frame: From 12 to 24 months post-transplant ]
- Average Weighted Hemoglobin (Hb) During Transfusion Independence (TI) [ Time Frame: From 12 to 24 months post-transplant ]
- Proportion of Participants who meet the Definition of Transfusion Reduction (TR) [ Time Frame: From 12 to 24 months post-transplant ]TR is defined as demonstration of a 60 percent (%) reduction in the annualized volume of pRBC transfusion requirements (in milliliter per kilogram [mL/kg]) in the post-treatment time period from 12 Months post-drug product infusion through Month 24 compared to the annualized mL/kg pRBC transfusion requirement during the 24 months prior to study enrollment
- Proportion of Participants with At Least 50%, 60%, 75%, 90% or 100% Reduction in the Annualized pRBCs Transfusion [ Time Frame: From 12 to 24 months post-transplant ]Reduction in the annualized mL/kg pRBCs transfused from 12 months post-drug product infusion through Month 24 (approximately a 12-month period) of at least 50%, 60%, 75%, 90% or 100% compared to the annualized mL/kg pRBC transfusion requirement during the 24 months prior to enrollment.
- Annualized Number of pRBC Transfusions [ Time Frame: From 12 to 24 months post-transplant ]Annualized number of pRBC transfusions from 12 months post-drug product infusion through Month 24 compared to the annualized number of transfusions during the 24 months prior to enrollment.
- Annualized Volume of pRBC Transfusions [ Time Frame: From 12 to 24 months post-transplant ]Annualized volume of pRBC transfusions from 12 months post-drug product infusion through Month 24 compared to the annualized volume of transfusions during the 24 months prior to enrollment.
- Time From Drug Product Infusion to Last pRBC Transfusion [ Time Frame: Up to 24 months post-transplant ]
- Time From Last pRBC Transfusion to 24 Months [ Time Frame: Up to 24 months post-transplant ]
- Weighted Average Nadir Hemoglobin (Hb) [ Time Frame: From 12 to 24 months post-transplant ]Weighted average nadir Hb during the 24 months prior to enrollment compared to weighted average nadir Hb from 12 months post-drug product infusion through the Month 24 Visit.
- Unsupported Total Hb Levels Over Time [ Time Frame: At Month 6, 9, 12, 18 and 24 ]
- Unsupported Total Hb Levels (>=10 g/dL, >=11 g/dL, >=12 g/dL, >=13 g/dL, and >=14 g/dL) [ Time Frame: At Month 6, 12, 18 and 24 ]
- Proportion of Participants Who Have Not Received Chelation Therapy for At Least 6 Months Following Drug Product Infusion [ Time Frame: From 6 to 24 months ]
- Time From Last Iron Chelation Use to Last Follow-up [ Time Frame: Up to 24 months ]
- Proportion of Participants Using Therapeutic Phlebotomy and Annualized Frequency of Phlebotomy [ Time Frame: Up to 24 months ]
- Change From Baseline in Liver Iron Content by Magnetic Resonance Imaging (MRI) [ Time Frame: Baseline, Month 12 and 24 ]
- Change From Baseline in Cardiac T2 on MRI [ Time Frame: Baseline, Month 12 and 24 ]
- Change From Baseline in Serum Ferritin [ Time Frame: Baseline, Month 12 and 24 ]
- Change From Baseline in Pediatric Quality of Life Inventory (PedsQL) Generic Core Scale (GCS) Score [ Time Frame: Baseline, Month 12 and 24 ]PedsQL GCS is designed to measure health-related quality of life in pediatric participants and adolescents (2 to 18 years of age). It encompasses 4 dimensions of functioning (physical [8 items], emotional [5 items], social [5 items], school [3 items]). Age groups: Toddler (2-4 years), Young pediatric (5-7 years), Pediatric (8-12 years), and Teens (13-18 years). Depending on the participant's age, the questionnaire may be completed by parent/caregiver as appropriate. For the Toddler group, the PedsQL GCS consist of 21 items, using a 5-point Likert scale (0 to 4); for all other groups, the PedsQL GCS consist of 23 items, with a 3-point Likert scale (0, 2, 4) for the young pediatric, and a 5-point Likert scale for the pediatric and teens groups. Scores are transformed on a scale from 0 to 100 where 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicate improved quality of life.
- Change From Baseline in EuroQol-5D (Youth version) (EQ-5D-Y) [ Time Frame: Baseline, Month 12 and 24 ]EQ-5D-Y health questionnaire is a participant answered questionnaire scoring 5 dimensions - mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The EQ-5D total score ranges from 0 (worst health state) to 1 (perfect health state) and 1 reflects the best outcome.
- Change From Baseline in EuroQol-5D (EQ-5D) [ Time Frame: Baseline, Month 12 and 24 ]The EQ-5D provides a descriptive profile and index value for health status. The questionnaire measures 5 dimensions of health status: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. For each dimension, there are 5 levels of response: no problems, slight problems, moderate problems, severe problems, and unable to do/extreme problems.
- Change From Baseline in Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) Questionnaire Score [ Time Frame: Baseline, Month 12 and 24 ]The FACT-BMT assesses bone marrow transplant related concerns. The total score is the sum of sub-scale scores for 5 domains: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, and Bone Marrow Transplantation Subscale. Within each domain, a 5-point Likert-type scale (from 0-4) is used to measure the responses for each question. After taking into account reverse scores for questions constructed in a negative form, the subscale score for each domain is calculated by multiplying the sum of the item scores by the number of items in the subscale, then dividing by the number of items answered. The final score for FACT-BMT ranges from 0 to 148. Higher scores indicate better quality of life.
- Change From Baseline in Short Form-36 Health Survey (SF-36), Version 2 [ Time Frame: Baseline, Month 12 and 24 ]SF-36 is a generic quality-of-life instrument that had been widely used to assess HRQL of participants. Generic instruments were used in general populations to assess a wide range of domains applicable to a variety of health states, conditions, and diseases. The SF-36 consisted of 36 items that were aggregated into 8 multi-item scales (physical functioning [1=yes, limited a lot to 3=no, not limited at all], role-physical [1=all of the time to 5=none of the time], bodily pain [1=very severe to 6=none], general health [1=poor to 5=excellent], vitality [1=none of the time to 5=all of the time], social functioning [1=all of the time: to 5=none of the time], role emotional [1=all of the time to 5=none of the time] and mental health [1=all of the time to 5=none of the time]), with scores ranged from 0 to 100. Higher scores indicating better HRQL.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||0 Years to 50 Years (Child, Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
• Participants less than or equal to (<=) 50 years of age at the time of consent or assent (as applicable), and able to provide written consent (adults, or legal guardians, as applicable) or assent (adolescents or children). Provided that the data monitoring committee (DMC) has approved enrolling participants younger than 5 years of age, participants younger than 5 years of age may be enrolled if they weigh a minimum of 6 kilograms (kg) and are reasonably anticipated to be able to provide at least the minimum number of cells required to initiate the manufacturing process.
- Diagnosis of TDT with a history of at least 100 milliliter per kilogram per year (mL/kg/year) of pRBCs in the 2 years preceding enrollment (all participants), or be managed under standard thalassemia guidelines with >= 8 transfusions of pRBCs per year in the 2 years preceding enrollment (participants >=12 years).
- Clinically stable and eligible to undergo HSCT.
- Treated and followed for at least the past 2 years in a specialized center that maintained detailed medical records, including transfusion history.
- Presence of a mutation characterized as other then β0 (e.g., β+, βE, βC) on at least one β-globin gene (HBB) allele.
- Positive for presence of human immunodeficiency virus type 1 or 2 (HIV-1 and HIV-2), hepatitis B virus (HBV), or hepatitis C (HCV).
- A white blood cell (WBC) count less than (<) 3×10^9/liter (L), and/or platelet count <100×10^9/L not related to hypersplenism.
- Uncorrected bleeding disorder.
- Any prior or current malignancy.
- Prior HSCT.
- Advanced liver disease.
- A cardiac T2* <10 ms by MRI.
- Any other evidence of severe iron overload that, in the investigator's opinion, warrants exclusion.
- Participation in another clinical study with an investigational drug within 30 days of Screening.
- Any other condition that would render the participant ineligible for HSCT, as determined by the attending transplant physician or investigator.
- Prior receipt of gene therapy.
- Pregnancy or breastfeeding in a postpartum female or absence of adequate contraception for fertile participant.
- A known and available human leukocyte antigen (HLA) matched family donor.
- Any contraindications to the use of granulocyte colony stimulating factor (G-CSF) and plerixafor during the mobilization of hematopoietic stem cells and any contraindications to the use of busulfan and any other medicinal products required during the myeloablative conditioning, including hypersensitivity to the active substances or to any of the excipients.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03207009
|United States, California|
|UCSF Benioff Children's Hospital Oakland|
|Oakland, California, United States, 94609|
|United States, Illinois|
|Ann & Robert H. Lurie Children's Hospital of Chicago|
|Chicago, Illinois, United States, 60611|
|United States, Pennsylvania|
|Children's Hospital of Philadelphia|
|Philadelphia, Pennsylvania, United States, 19104|
|Hopital d'enfants de la Timone|
|Marseille, France, 13385|
|Hannover Medical School|
|Hannover, Germany, 30625|
|University of Heidelberg|
|Heidelberg, Germany, 69120|
|General Hospital of Thessaloniki 'G.Papanikolaou'|
|IRCCS Ospedale Pediatrico Babino Gesu|
|University College London Hospital|
|London, United Kingdom|
|Study Director:||Himal L Thakar, MD||bluebird bio|
|Responsible Party:||bluebird bio|
|Other Study ID Numbers:||
|First Posted:||July 2, 2017 Key Record Dates|
|Last Update Posted:||April 4, 2023|
|Last Verified:||February 2022|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Anemia, Hemolytic, Congenital
Genetic Diseases, Inborn